Objective: To assess the potential value of maternal serum alpha-fetoprotein (AFP) at 11–13 weeks’ gestation in early screening for fetal neural tube defects (NTDs). Methods: Maternal serum AFP at 11–13 weeks’ gestation was measured in 32 cases of fetal NTDs, including 18 cases of acrania and 14 cases of spina bifida, and 1,500 unaffected controls. The measured serum AFP was converted into multiple of the expected median (MoM) after adjustment for gestational age and maternal characteristics and Mann-Whitney test was used to determine the significance of difference in the mean MoM of serum AFP in the NTD group to that in the controls. Results: The mean AFP MoM in the NTD group (1.76, 95% CI 1.39–2.23) was significantly higher than in the controls (p < 0.0001). The mean AFP MoM was not significantly different between the cases of acrania and cases of spina bifida (1.78 vs. 1.75; p = 0.722). The detection rates of NTD in screening by serum AFP were 50.0% (95% CI 31.9–68.1) and 37.5% (95% CI 21.1–56.3) at fixed false-positive rates of 10 and 5%, respectively. Conclusion: Measurement ofmaternal serum AFP at 11–13 weeks’ gestation may be useful in screening for fetal NTDs.

Keywords:
Alpha-fetoprotein, Neural tube defects, Acrania, Spina bifida, First-trimester screening
1.
Leighton PC, Kitau MJ, Chard T, Gordon YB, Leek AE: Levels of alpha-fetoprotein in maternal blood as a screening test for fetal neural-tube defect. Lancet 1975;ii:1012–1015.
2.
Merkatz IR, Nitowsky HM, Macri JN, Johnson WE: An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984;148:886–894.
3.
Wald NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FP: Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of UK collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet 1977;i:1323–1332.
4.
Nicolaides KH, Campbell S, Gabbe SG, Guidetti R: Ultrasound screening for spina bifida: cranial and cerebellar signs. Lancet 1986;ii:72–74.
5.
Nicolaides KH, Azar GB, Byrne D, Mansur CA, Marks K: Fetal nuchal translucency: ultrasound screening for chromosomal defects in the first trimester of pregnancy. Br Med J 1992;304:867–869.
6.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH: A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231–237.
7.
Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011;29:183–196.
8.
Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH: First-trimester screening for trisomy 21 using alpha-fetoprotein. Fetal Diagn Ther 2011;30:215–218.
9.
Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH: Maternal serum α-fetoprotein at 11–13 weeks’ gestation in spontaneous early preterm delivery. Fetal Diagn Ther 2011;30:88–93.
10.
Robinson HP, Fleming JE: A critical evaluation of sonar ‘crown-rump length’ measurements. Br J Obstet Gynaecol 1975;82:702–710.
11.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH: Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free β-hCG and pregnancy-associated plasma protein-A. Hum Reprod 2008;23:1968–1975.
12.
Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH: Maternal serum AFP in normal pregnancy at 11–13 weeks’ gestation. Fetal Diagn Ther 2011;30:274–279.
13.
Aitken DA, McCaw G, Crossley JA, Berry E, Connor JM, Spencer K, Macri JN: First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects. Prenat Diagn 1993;13:681–689.
14.
Wald NJ, Hackshaw A, Stone R, Densem J: Serum alpha-fetoprotein and neural tube defects in the first trimester of pregnancy. MRC Vitamin Study Research Group. Prenat Diagn 1993;13:1047–1050.
15.
Brock DJ, Scrimgeour JB, Nelson MM: Amniotic fluid alphafetoprotein measurements in the early prenatal diagnosis of central nervous system disorders. Clin Genet 1975;7:163–169.
16.
Report of the Collaborative Acetylcholinesterase Study: Amniotic fluid acetylcholinesterase electrophoresis as a secondary test in the diagnosis of anencephaly and open spina bifida in early pregnancy. Lancet 1981;15:321–324.
17.
Nicolaides KH, Campbell S, Gabbe SG, Guidetti R: Ultrasound screening for spina bifida: cranial and cerebellar signs. Lancet 1986;ii:72–74.
18.
Van den Hof MC, Nicolaides KH, Campbell J, Campbell S: Evaluation of the lemon and banana signs in one hundred and thirty fetuses with open spina bifida. Am J Obstet Gynecol 1990;162:322–327.
19.
Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH: Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks. Prenat Diagn 2011;31:90–102.
20.
Sebire NJ, Noble PL, Thorpe-Beeston JG, Snijders RJM, Nicolaides KH: Presence of the ‘lemon’ sign in fetuses with spina bifida at the 10–14-week scan. Ultrasound Obstet Gynecol 1997;10:403–405.
21.
Chaoui R, Benoit B, Mitkowska-Wozniak H, Heling KS, Nicolaides KH: Assessment of intracranial translucency (IT) in the detection of spina bifida at the 11–13-week scan. Ultrasound Obstet Gynecol 2009;34:249–252.
22.
Lachmann R, Chaoui R, Moratalla J, Picciarelli G, Nicolaides KH: Posterior brain in fetuses with open spina bifida at 11 to 13 weeks. Prenat Diagn 2011;31:103–106.
23.
Lachmann R, Picciarelli G, Moratalla J, Greene N, Nicolaides KH: Frontomaxillary facial angle in fetuses with spina bifida at 11–13 weeks’ gestation. Ultrasound Obstet Gynecol 2010;36:268–271.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.